UK to deliberately infect volunteers with Covid-19 to test vaccines’ efficacy

By: Express Web Desk | Updated: September 24, 2020 12:23:01 pm

Coronavirus Vaccine, China vaccine, Covid-19 vaccinem WHO, WHO vaccine program, Trump, China-Trump, world news, Indian expressUnder phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city. (Photographer: Silvio Avila/AFP via Getty Images)

The United Kingdom could become the first in the world to deliberately infect healthy volunteers with coronavirus to study the effectiveness of vaccine candidates, the Financial Times reported.

The “Covid-19 human challenge trials” are likely to begin in January at a quarantine site in London, the report said, with around 2,000 people expressing interest so far.

Volunteers who qualify for the trials will be injected with an experimental vaccine before being administered a dose of Sars-Cov-2, the virus that causes Covid-19, under controlled conditions. It did not name the vaccines that would be assessed in the project. British drugmaker AstraZeneca, and French firm Sanofi both told Reuters that their vaccine candidates were not involved in the programme.

1Day Sooner, a US-based advocacy group campainging for Covid-19 infection trials, has petitioned the British Parliament seeking funds to build a containment facility with the capacity to quarantine 100 to 200 participants.

Imperial College London, reportedly the academic lead on the trials, did not confirm the studies.

“Imperial continues to engage in a wide range of exploratory discussions relating to COVID-19 research, with a variety of partners. We have nothing further to report at this stage,” a spokeswoman said, asked about the possibility of challenge trials.

However, any Covid-19 challenge trial will need to be approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and an independent research ethics committee.

“Human challenge trials can be helpful for the development of vaccines and can provide early evidence of clinical efficacy, particularly when there are low rates of infection of the virus in the population,” said the MHRA.

“The safety of trial participants is our top priority and any proposal from a developer to include a human infection challenge as part of a clinical trial for development of a vaccine would be considered on a benefit-risk basis, with risks monitored for and minimised in the proposed trial design.”

The UK government and the MHRA did not immediately respond to news agency Reuters’ requests for comment, but 1Day Sooner, welcomed the report. “1Day Sooner congratulates the British government on their plans to conduct challenge trials to test vaccines,” it said in a statement, confirming it would petition the government to house the trial participants.

with inputs from Reuters

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

© IE Online Media Services Pvt Ltd


hacklink al hd film izle php shell indir siber güvenlik türkçe anime izle Fethiye Escort android rat duşakabin fiyatları fud crypter hack forum mobil ödeme bozdurmaMobil Ödeme Nakite Çevirmebuy instagram followershtml nullednulled themesMobil Ödeme BozdurmaMobil Ödeme Nakite Çevirme1xbetdizipal